Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Neurol Neurosurg Psychiatry
Glavni autori: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Neuromuscular
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://ncbi.nlm.nih.gov/pubmed/31292200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2019-320998
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items